Navigation Links
Epizyme Receives Orphan Drug Designation for EPZ-5676
Date:8/16/2013

CAMBRIDGE, Mass., Aug. 16, 2013 /PRNewswire-USNewswire/ -- Epizyme, Inc., (NASDAQ: EPZM) a clinical stage biopharmaceutical company creating innovative personalized therapeutics for patients with genetically defined cancers, announced today that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation for EPZ-5676. Criteria for orphan drug designation requires that the product be intended for treatment of a rare disease or condition, classified as affecting fewer than 200,000 people in the United States.

Orphan drug designation allows special incentives for sponsors planning to test a product for use in a rare disease or condition. These incentives include tax credits, research and development grant funding and reduced filing fees during development or at the time of application for marketing approval. Once approved, the product may qualify for seven years of marketing exclusivity independent of any other intellectual property.

About EPZ-5676

Epizyme is developing EPZ-5676, a small molecule inhibitor of DOT1L created with Epizyme's proprietary product platform, for the treatment of acute leukemias in which the MLL gene is rearranged due to a chromosomal translocation (MLL-r). Due to the translocation, DOT1L is recruited to specific locations in the chromosome where it would not normally be present. As a result, DOT1L causes inappropriate methylation at these locations, which results in the increased expression of genes causing leukemia.

In September 2012, Epizyme initiated a Phase 1 clinical trial for EPZ-5676. The company believes EPZ-5676 is the first HMTi to enter human clinical development. As of August 2013, this program is in the dose escalation phase and is expected to initiate an expansion phase in the second half of 2013 that wil
'/>"/>

SOURCE Epizyme, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Epizyme Publishes Current Review on Targeting Protein Methyltransferases for Personalized Cancer Therapeutics
2. Epizyme to Present at Upcoming Conferences in February
3. Epizyme to Partner to Develop DOT1L Companion Diagnostic
4. Epizyme, Inc. Files Registration Statement for Proposed Initial Public Offering
5. Epizyme, Inc. Announces Pricing of Initial Public Offering
6. Epizyme Enrolls First Patient in Phase 1/2 Clinical Trial of EPZ-6438, an Inhibitor of EZH2
7. Epizyme, Inc. to Webcast Conference Call Discussing Second Quarter 2013 Financial Results on July 31, 2013
8. Epizyme, Inc. to Present at Wedbush Securities Life Sciences Management Access Conference in August
9. PAREXEL Chief Operating Officer Dr. Mark A. Goldberg Receives Special Recognition Award
10. Leica Biosystems Receives FDA Approval for the Fully Automated Bond Oracle™ HER2 IHC System on the Leica BOND-MAX
11. Nephros Receives 510(k) Clearance for Hemodiafiltration System
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/29/2015)... MENLO PARK, Calif. , May 29, ... (OTCQX: DMPI) ("DelMar" and the "Company"), a biopharmaceutical ... therapies in new orphan drug indications, presented additional ... Cancer Research (AACR) Advances in Brain Cancer Research ... product candidate VAL-083 (dianhydrogalactitol) to treat ...
(Date:5/29/2015)... -- World-renowned prostate surgeon and New York Urologist, Dr. David ... MR/Ultrasound Fusion-Guided Biopsy for detecting aggressive prostate cancer ... at Lenox Hill Hospital is the only center using the ... York City . We,ve seen tremendous improvement in detecting ... of an MRI makes for a much more accurate diagnosis, ...
(Date:5/28/2015)... HOUSTON , May 28, 2015 /PRNewswire/ - ESSA Pharma ... results for the second quarter and three and six months ... in Canadian dollars and in accordance with International Financial Reporting ... ESSA recorded a net loss of $5.9 million ($0.35 per ... (Q2-2015), compared to a net loss of $0.4 million ($0.03 ...
Breaking Medicine Technology:DelMar Pharmaceuticals Presents Additional Data on the Potential of VAL-083 in the Treatment of Temozolomide-Resistant Glioblastoma Multiforme 2DelMar Pharmaceuticals Presents Additional Data on the Potential of VAL-083 in the Treatment of Temozolomide-Resistant Glioblastoma Multiforme 3DelMar Pharmaceuticals Presents Additional Data on the Potential of VAL-083 in the Treatment of Temozolomide-Resistant Glioblastoma Multiforme 4DelMar Pharmaceuticals Presents Additional Data on the Potential of VAL-083 in the Treatment of Temozolomide-Resistant Glioblastoma Multiforme 5MR/Ultrasound Fusion-Guided Biopsy Better Able to Detect Aggressive Prostate Cancer, New Study Says 2Essa Pharma Inc. Reports Second Quarter 2015 Financial Results 2Essa Pharma Inc. Reports Second Quarter 2015 Financial Results 3Essa Pharma Inc. Reports Second Quarter 2015 Financial Results 4Essa Pharma Inc. Reports Second Quarter 2015 Financial Results 5
... 9 Isis Pharmaceuticals, Inc. (Nasdaq: ISIS ... with eight presentations (including three oral talks and two ... Scientific Sessions in New Orleans by Isis and its ... ISIS-SGLT2Rx showing a robust and sustained reduction in sodium ...
... for America,s Health (TFAH) and the Robert Wood Johnson ... which finds that Americans rank prevention as the most ... funding for prevention programs to reduce disease and keep ... conducted by Greenberg Quinlan Rosner Research and Public Opinion ...
Cached Medicine Technology:Isis Highlights New Data on Antisense Drugs to Treat Type 2 Diabetes and Obesity at ADA Scientific Sessions 2Isis Highlights New Data on Antisense Drugs to Treat Type 2 Diabetes and Obesity at ADA Scientific Sessions 3Isis Highlights New Data on Antisense Drugs to Treat Type 2 Diabetes and Obesity at ADA Scientific Sessions 4Isis Highlights New Data on Antisense Drugs to Treat Type 2 Diabetes and Obesity at ADA Scientific Sessions 5Isis Highlights New Data on Antisense Drugs to Treat Type 2 Diabetes and Obesity at ADA Scientific Sessions 6New Poll Finds Disease Prevention is Top Priority for Americans in Health Reform 2New Poll Finds Disease Prevention is Top Priority for Americans in Health Reform 3New Poll Finds Disease Prevention is Top Priority for Americans in Health Reform 4New Poll Finds Disease Prevention is Top Priority for Americans in Health Reform 5
(Date:5/29/2015)... Dot Hill can mark one more item off her bucket list: ... retirement community is the oldest woman to have flown at ... great fun!”, she exclaimed. “I’ve always wanted to jump from ... thought this would be ok.” , “We put on nylon coveralls, ... described. “I don’t remember it being noisy, but the wind ...
(Date:5/29/2015)... Los Angeles, CA (PRWEB) May 29, 2015 ... Old Should You Really be When You Get Botox ... anti-aging questions according to Google. Elle partnered with Google to ... these questions. The most searched question in California, for example, ... South Carolina the most common search query is what's the ...
(Date:5/29/2015)... Jan Wooden Howse lost her husband and ... all else: God does no wrong. , It’s fitting, then, ... passing is titled “God Does No Wrong.” It focuses on ... personal tragedy. , “My story has a positive message ... into something productive, something healing,” Howse said. , “God Does ...
(Date:5/29/2015)... 29, 2015 Johnson & Johnson ... confidential Risperdal lawsuit ( http://www.risperdallawsuit2014.com/ ) settlement with ... to his use of the antipsychotic medication. According ... for the third bellwether trial to involve male ... underway in Pennsylvania’s Philadelphia Court of Common Pleas, ...
(Date:5/29/2015)... Diego, California (PRWEB) May 29, 2015 A ... Core” and have joined the national effort to teach this ... parents in the U.S. have been “sickened” by the recent ... However, love it or hate it, Common Core is now ... District of Columbia. Parents are now seeking ways to ...
Breaking Medicine News(10 mins):Health News:Indoor Skydiving Brings Thrills to Seniors 2Health News:Botox, Wrinkles and Double Chins: The Most-Asked Beauty Problems According to Google 2Health News:Turning grief from a child’s passing into virtue 2Health News:Risperdal Lawsuit Selected as Pennsylvania’s Third Bellwether Gynecomastia Case Settles Hours Before Trial 2Health News:Risperdal Lawsuit Selected as Pennsylvania’s Third Bellwether Gynecomastia Case Settles Hours Before Trial 3Health News:Doctors Discover a Cure for the Common Core 2
... FASgen is pleased to report the,publication of ... one of the Company,s proprietary compounds. In a ... supported,research into the selective inhibition of fatty acid ... potential therapeutic agent against various,forms of solid tumor ...
... KAYSVILLE, Utah, Dec. 28 A Utah company wants ... Virtual Trainer Pro.,MediaRif,s online software takes the complexity out ... Strength training is on the rise, and not just ... reports that 21.9% of women use,strength training as a ...
... KV,s Securities until February 15, ... ... KV Pharmaceutical Company,(NYSE: KVa/KVb) a fully integrated specialty pharmaceutical company ... products,announced today that NYSE Regulation, Inc. has granted KV,s request for ...
... 28 Caraco Pharmaceutical,Laboratories, Ltd., (Amex: CPD ) ... has granted final approval for the Company,s,Abbreviated New Drug ... 5 mg and 10 mg, (Cetirizine HCl)., Cetirizine ... products in,two strengths of 5 mg and 10 mg, ...
... Therapeutics Inc.,("Transition" or the "Company") (TSX: TTH; NASDAQ: ... has been appointed Vice President of,Business Development. Since ... key member of the Company,s management team and ... a broad range of activities,including licensing and intellectual ...
... that contact with some commonly used pesticides in farm work ... women are an understudied occupational group, said Jane Hoppin, Sc.D., ... author of the study. More than half the women in ... about the risks. , The study was published in the ...
Cached Medicine News:Health News:Personal Fitness Training Goes Online for 2008 2Health News:KV Pharmaceutical Company Announces NYSE Listing Extension 2Health News:KV Pharmaceutical Company Announces NYSE Listing Extension 3Health News:Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic OTC Versions of Zyrtec Allergy Tablets(R) and Zyrtec Hives Relief Tablets(R) 2Health News:Transition Therapeutics Announces Appointment of Vice-President of Business Development 2Health News:Handling pesticides associated with greater asthma risk in farm women 2
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
Medicine Products: